←
Kate Sears10,759 posts
Kate Sears avatar✓

Kate Sears ✓

@OpenMedKate

Hi I'm Kate, community lead for @OpenMedicineHQ. Open access and free for everyone.

◷ Joined February 2017▧ 797 Photos and videos
Open Medicine Insights avatar
⟳ Kate Sears retweeted
Open Medicine Insights@OpenMedInsights·21h

· Open Medicine Algorithm Spotlight · Hypernatremia Diagnostic Evaluation: Stepwise Clinical and Laboratory Approach (by @iamnephrologist) @OpenMedicineHQ Key points: - Concordance among sodium, measured osmolality, glucose, and measurement method distinguishes true hypertonic hypernatremia from analytical or osmolar discordance. - Neurologic findings reflect the severity and rapidity of hypertonicity, while hemodynamic and physical findings determine whether urgent volume resuscitation is required. - Classification as hypovolemic, euvolemic, or hypervolemic is a standard organizing step that narrows the balance of total-body water and sodium. ** Hypovolemic hypernatremia reflects combined sodium and water loss with proportionally greater water loss; orthostasis, tachycardia, low venous pressure, and prerenal kidney injury are supportive. ** Euvolemic hypernatremia usually represents relatively pure water loss through renal or extrarenal routes without clinically apparent sodium depletion or overload. ** Volume overload accompanying hypernatremia should prompt evaluation for hypertonic sodium administration, ingestion, dialysis-related loading, or less commonly mineralocorticoid-mediated retention. LIVING algorithm link: myopenmedicine.com/algorithm… #OpenMedicine #Nephrology #NephTwitter #KidneyDisease #NephPearls #InternalMedicine @OpenMedKate @scserendipity1

Simon C avatar
⟳ Kate Sears retweeted
Simon C@scserendipity1·11h

We are formed Open Medicine to be a free resource for the World! My clever fellow founder AG said let’s build the ‘Wikipedia of medicine’… I wasn’t convinced but with our wonderful clinical faculty and my other founder EK and his software team providing support it is happening Thank you @iamnephrologist thank you Open Medicine Foundation Circle! @DrChoueiri (our number 1) @neerajaiims @VincentRK @StephenVLiu @drallysonocean @drallysonocean @KapoorNitinDr @AzadOncology @cpeedell @AlisonBirtle @brian_rini @CharuAggarwalMD @shilpaonc @Dr_R_Kurzrock @OpenMedKate @drsarahsam @scocmem @BalazsHalmosMD @OncoThor

Harold J. Burstein, MD, PhD, FASCO avatar
⟳ Kate Sears retweeted
Harold J. Burstein, MD, PhD, FASCO@DrHBurstein·21h

These kinds of surveys are based on a false assumption that there is a specific optimal sequence of treatment in advanced, ER+ breast cancer. The better metaphor is of a buffet table. You are going to have the chance to try everything, and the sequence of treatment is dictated by what appeals at the moment based on clinical cancer burden, prior therapy, biomarkers (to some degree), and treatment logistics/safety/tolerability profile. Every clinician knows this. We should resist the KOL- and pharma-driven desire to specify a treatment plan in the absence of any data, absence of studies comparing one in-class drug versus another, absence of studies designed to test real sequences of treatment vs generating FDA approvals.

Paolo Tarantino avatar
⟳ Kate Sears retweeted
Paolo Tarantino@PTarantinoMD·Nov 16

65yo patient with de-novo, HR+/HER2- MBC (bone, lymph nodes). After 2 years on letrozole + ribociclib, she develops two new small liver mets, biopsy confirmed ER+ mBC. No symptoms, normal LFTs. ctDNA shows ESR1 and PIK3CA mutations. What would you prescribe next?

Saad Z. Usmani MD MBA FASCO 🇺🇸🇵🇰 avatar
⟳ Kate Sears retweeted
Saad Z. Usmani MD MBA FASCO 🇺🇸🇵🇰@szusmani·Nov 16

I just finished reviewing the #ASH26 #mmsm abstracts and will share my favorites so far, subject to change during the live meeting in New Orleans, LA December 12-15 2026. Let's start with the frontline setting: Optimizing VRd: Does more bortezomib necessarily mean better treatment? REMNANT evaluated weekly vs twice-weekly bortezomib during VRd induction/consolidation in transplant-eligible NDMM (n=381). Peripheral neuropathy: 40.3% vs 75.5%. Grade 2–3 neuropathy: 13.8% vs 41.0%. MRD-negative CR: 31.5% vs 34%. Weekly dosing substantially reduced neuropathy and dose reductions, with similar MRD-negative CR rates. A practice validating study, will influence future SOC study arms. onlineprogram.hematology.org… 1/17 @MSKCancerCenter @MSK_DeptOfMed @FrancescoMaura4 @kordeneha1 @UrviShahMD @MalinHultcrantz @ejurgens @GunjanLShah @LesokhinMD

Uriel Suárez avatar
⟳ Kate Sears retweeted
Uriel Suárez@UsuarezMD·Nov 15

What the Robot Still Can’t Do | New England Journal of Medicine nejm.org/doi/abs/10.1056/NEJ… “Until someone does, I will keep showing up to the exam room and for the patient across the table and increasingly let the AI play chess while I remember how to be a physician.” @DrNundy Great perspective in @NEJM

Open Medicine Insights avatar
⟳ Kate Sears retweeted
Open Medicine Insights@OpenMedInsights·Nov 16

· Open Medicine Algorithm Spotlight · Clinical Decision-Making for Obinutuzumab in Glomerular Disease (@iamnephrologist) | @OpenMedicineHQ Key points: - Regulatory status and evidence differ substantially by disease: primary MN, active LN, and childhood-onset FRNS/SDNS are approved, whereas AAV and other glomerulopathies remain off-label. - Confirm active immune-mediated disease and obtain CBC with differential and platelets, serum creatinine/eGFR, liver tests, quantitative immunoglobulins, HBsAg and anti-HBc. - Active Immune Disease Likely to Benefit From B-Cell Depletion? B-cell depletion should be reserved for an appropriate immune-mediated diagnosis with potentially reversible activity rather than isolated chronic scarring or nonimmune proteinuria. - No—chronic scarring or alternative cause: Do Not Initiate Obinutuzumab; Treat Barrier or Redirect. LIVING algorithm link:myopenmedicine.com/algorithm… #OpenMedicine #Nephrology #NephTwitter #KidneyDisease #NephPearls @OpenMedKate @scserendipity1